Display options
Cite
Pesce S, Thoren FB, Cantoni C, et al. The Innate Immune Cross Talk between NK Cells and Eosinophils Is Regulated by the Interaction of Natural Cytotoxicity Receptors with Eosinophil Surface Ligands. Front Immunol. 2017;8:510doi: 10.3389/fimmu.2017.00510.
Pesce, S., Thoren, F. B., Cantoni, C., Prato, C., Moretta, L., Moretta, A., & Marcenaro, E. (2017). The Innate Immune Cross Talk between NK Cells and Eosinophils Is Regulated by the Interaction of Natural Cytotoxicity Receptors with Eosinophil Surface Ligands. Frontiers in immunology, 8510. https://doi.org/10.3389/fimmu.2017.00510
Pesce, Silvia, et al. "The Innate Immune Cross Talk between NK Cells and Eosinophils Is Regulated by the Interaction of Natural Cytotoxicity Receptors with Eosinophil Surface Ligands." Frontiers in immunology vol. 8 (2017): 510. doi: https://doi.org/10.3389/fimmu.2017.00510
Pesce S, Thoren FB, Cantoni C, Prato C, Moretta L, Moretta A, Marcenaro E. The Innate Immune Cross Talk between NK Cells and Eosinophils Is Regulated by the Interaction of Natural Cytotoxicity Receptors with Eosinophil Surface Ligands. Front Immunol. 2017 Apr 28;8:510. doi: 10.3389/fimmu.2017.00510. eCollection 2017. PMID: 28503177; PMCID: PMC5408020.
Copy Download .nbib Format: NLM
Share it on

Front Immunol. 2017 Apr 28;8:510. doi: 10.3389/fimmu.2017.00510. eCollection 2017.

The Innate Immune Cross Talk between NK Cells and Eosinophils Is Regulated by the Interaction of Natural Cytotoxicity Receptors with Eosinophil Surface Ligands.

Frontiers in immunology

Silvia Pesce, Fredrik B Thoren, Claudia Cantoni, Carola Prato, Lorenzo Moretta, Alessandro Moretta, Emanuela Marcenaro

Affiliations

  1. Dipartimento di Medicina Sperimentale, Università degli Studi di Genova, Genova, Italy.
  2. Sahlgrenska Cancer Center, University of Gothenburg, Göteborg, Sweden.
  3. Istituto Giannina Gaslini, Genova, Italy.
  4. Centro di Eccellenza per le Ricerche Biomediche, Università degli Studi di Genova, Genova, Italy.
  5. Department of Immunology, IRCCS Bambino Gesù Children's Hospital, Rome, Italy.

PMID: 28503177 PMCID: PMC5408020 DOI: 10.3389/fimmu.2017.00510

Abstract

Previous studies suggested that the cross talk between NK cells and other cell types is crucial for the regulation of both innate and adaptive immune responses. In the present study, we analyzed the phenotypic and functional outcome of the interaction between resting or cytokine-activated NK cells and eosinophils derived from non-atopic donors. Our results provide the first evidence that a natural cytotoxicity receptor (NCR)/NCR ligand-dependent cross talk between NK cells and eosinophils may be important to upregulate the activation state and the effector function of cytokine-primed NK cells. This interaction also promotes the NK-mediated editing process of dendritic cells that influence the process of Th1 polarization. In turn, this cross talk also resulted in eosinophil activation and acquisition of the characteristic features of antigen-presenting cells. At higher NK/eosinophil ratios, cytokine-primed NK cells were found to kill eosinophils

Keywords: NK cells; cross talk; cytotoxicity; dendritic cells; eosinophils; innate cells; natural cytotoxicity receptor

References

  1. J Immunol. 2012 Feb 15;188(4):1668-74 - PubMed
  2. PLoS One. 2012;7(6):e39170 - PubMed
  3. J Leukoc Biol. 2009 Jan;85(1):117-23 - PubMed
  4. Allergy Asthma Immunol Res. 2010 Apr;2(2):87-101 - PubMed
  5. J Leukoc Biol. 2004 Sep;76(3):520-7 - PubMed
  6. Clin Exp Allergy. 2008 May;38(5):709-50 - PubMed
  7. J Exp Med. 2009 Jul 6;206(7):1495-503 - PubMed
  8. J Exp Med. 1997 Oct 6;186(7):1129-36 - PubMed
  9. Semin Immunol. 2006 Jun;18(3):151-8 - PubMed
  10. J Exp Med. 2004 May 17;199(10):1331-41 - PubMed
  11. Eur J Immunol. 2004 Jun;34(6):1715-22 - PubMed
  12. J Allergy Clin Immunol. 2008 Feb;121(2):479-85 - PubMed
  13. Immunotherapy. 2011 Sep;3(9):1075-86 - PubMed
  14. Int Immunol. 2008 Sep;20(9):1155-67 - PubMed
  15. Clin Exp Allergy. 2008 Aug;38(8):1254-63 - PubMed
  16. Nat Rev Immunol. 2005 Mar;5(3):201-14 - PubMed
  17. Blood. 2013 Oct 24;122(17):2935-42 - PubMed
  18. PLoS One. 2014 Apr 11;9(4):e94492 - PubMed
  19. Am J Respir Cell Mol Biol. 2002 Apr;26(4):404-12 - PubMed
  20. Curr Opin Allergy Clin Immunol. 2010 Feb;10(1):14-9 - PubMed
  21. J Allergy Clin Immunol. 2004 Jan;113(1):30-7 - PubMed
  22. J Immunol. 2005 Dec 15;175(12):7989-95 - PubMed
  23. Immunity. 2007 Dec;27(6):965-74 - PubMed
  24. Blood. 2009 Nov 5;114(19):4108-16 - PubMed
  25. Immunology. 2011 Oct;134(2):198-213 - PubMed
  26. Immunol Cell Biol. 2010 Mar-Apr;88(3):250-6 - PubMed
  27. Trends Immunol. 2010 Jan;31(1):39-44 - PubMed
  28. Blood. 2005 Oct 1;106(7):2252-8 - PubMed
  29. Annu Rev Immunol. 1996;14:619-48 - PubMed
  30. Int Arch Allergy Immunol. 2006;140(4):277-84 - PubMed
  31. J Exp Med. 2002 Feb 4;195(3):343-51 - PubMed
  32. Annu Rev Immunol. 2001;19:291-330 - PubMed
  33. J Exp Med. 2005 Oct 3;202(7):941-53 - PubMed
  34. J Immunol. 2015 Aug 1;195(3):1121-8 - PubMed
  35. Proc Natl Acad Sci U S A. 2010 Dec 14;107(50):21659-64 - PubMed
  36. Blood. 2006 Mar 1;107(5):1996-2003 - PubMed
  37. J Immunol. 2005 Apr 1;174(7):3992-8 - PubMed
  38. Oncoimmunology. 2015 Jan 22;4(4):e1001224 - PubMed
  39. J Immunol Methods. 1991 Dec 15;145(1-2):105-10 - PubMed
  40. Transpl Immunol. 2006 Dec;17(1):16-9 - PubMed
  41. Science. 2011 Jan 7;331(6013):44-9 - PubMed
  42. J Immunol. 1993 Mar 15;150(6):2554-62 - PubMed
  43. J Immunol. 1998 Feb 1;160(3):1279-84 - PubMed
  44. J Immunol. 2007 Dec 1;179(11):7585-92 - PubMed
  45. Eur J Immunol. 2004 Jun;34(6):1663-72 - PubMed
  46. Cancer Immunol Immunother. 2012 Sep;61(9):1527-34 - PubMed
  47. J Immunol. 1990 Nov 1;145(9):2950-8 - PubMed
  48. Annu Rev Immunol. 1999;17:875-904 - PubMed
  49. Clin Exp Allergy. 2013 Mar;43(3):322-31 - PubMed
  50. Sci Transl Med. 2013 Feb 27;5(174):174ra26 - PubMed
  51. Blood. 2012 Nov 8;120(19):3882-90 - PubMed
  52. Cell Tissue Res. 2011 Jan;343(1):57-83 - PubMed
  53. Autoimmun Rev. 2005 Nov;4(8):520-5 - PubMed
  54. J Clin Invest. 1997 Jan 15;99(2):178-84 - PubMed
  55. Int Arch Allergy Immunol. 1999;120 Suppl 1:30-3 - PubMed
  56. Immunol Lett. 2008 Jun 15;118(1):88-95 - PubMed
  57. J Immunol. 2005 Jan 1;174(1):110-8 - PubMed
  58. Infect Immun. 2006 Jun;74(6):3232-8 - PubMed
  59. Blood. 2013 Apr 25;121(17):3396-401 - PubMed
  60. Cancer Immunol Res. 2014 Jan;2(1):1-8 - PubMed
  61. Nat Rev Immunol. 2002 Dec;2(12):957-64 - PubMed
  62. Nat Commun. 2014 Dec 04;5:5639 - PubMed
  63. Allergy. 2004 Mar;59(3):268-75 - PubMed
  64. J Exp Med. 1999 Nov 15;190(10):1505-16 - PubMed
  65. Proc Natl Acad Sci U S A. 1989 Feb;86(4):1348-51 - PubMed
  66. Immunology. 2012 May;136(1):11-20 - PubMed
  67. Blood. 2013 Jul 18;122(3):394-404 - PubMed
  68. Crit Rev Oncog. 2014;19(1-2):67-75 - PubMed
  69. Semin Cancer Biol. 2006 Oct;16(5):348-58 - PubMed
  70. J Clin Invest. 2000 Apr;105(7):945-53 - PubMed
  71. J Exp Med. 2002 Feb 4;195(3):F9-14 - PubMed
  72. Nat Immunol. 2004 Dec;5(12):1260-5 - PubMed
  73. Annu Rev Immunol. 2001;19:197-223 - PubMed
  74. Mediators Inflamm. 2011;2011:373589 - PubMed
  75. Blood. 2008 Sep 1;112(5):1776-83 - PubMed
  76. Semin Immunol. 2014 Apr;26(2):152-60 - PubMed

Publication Types